KRAS and non-small cell lung carcinoma: KRAS is the most commonly mutated oncogene in NSCLC, and this mutation is associated with a poor prognosis [64], with the G12C being the most frequent (40–50% of KRAS mutations), followed by G12V (19% of KRAS mutations) [65,66].